News
Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...
U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Asking people with type 2 diabetes their language and care preferences is vital to optimise outcomes globally, says Heather Koga As the US writer Ingrid Bengis said, “Words are a form of action, ...
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that human study GLP-1-H25-5 which ...
A recent analysis of adverse drug reactions by Indian Pharmacopoeia Commission revealed that combinations of beta-blockers ...
More than 6,700 University of Nebraska–Lincoln students have been named to the Deans’ List for the spring semester of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results